
Jurjan Aman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/579678/publications.pdf Version: 2024-02-01



Ιπριανί Διαάνι

#	Article	IF	CITATIONS
1	High titers and low fucosylation of early human anti–SARS-CoV-2 IgG promote inflammation by alveolar macrophages. Science Translational Medicine, 2021, 13, .	12.4	166
2	Effective Treatment of Edema and Endothelial Barrier Dysfunction With Imatinib. Circulation, 2012, 126, 2728-2738.	1.6	147
3	Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respiratory Medicine,the, 2021, 9, 957-968.	10.7	83
4	Targeting Abl Kinases to Regulate Vascular Leak During Sepsis and Acute Respiratory Distress Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1071-1079.	2.4	64
5	Using cultured endothelial cells to study endothelial barrier dysfunction: Challenges and opportunities. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L453-L466.	2.9	55
6	The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model. Frontiers in Cardiovascular Medicine, 2018, 5, 55.	2.4	47
7	Predictors of pulmonary edema formation during fluid loading in the critically ill with presumed hypovolemia*. Critical Care Medicine, 2012, 40, 793-799.	0.9	46
8	ROCK2 primes the endothelium for vascular hyperpermeability responses by raising baseline junctional tension. Vascular Pharmacology, 2015, 70, 45-54.	2.1	33
9	Reversal of Vascular Leak with Imatinib. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1171-1173.	5.6	27
10	Globular adiponectin controls insulin-mediated vasoreactivity in muscle through AMPKα2. Vascular Pharmacology, 2016, 78, 24-35.	2.1	26
11	Long-term clinical outcomes of COVID-19 patients treated with imatinib. Lancet Respiratory Medicine,the, 2022, 10, e34-e35.	10.7	22
12	Bosutinib prevents vascular leakage by reducing focal adhesion turnover and reinforcing junctional integrity. Journal of Cell Science, 2020, 133, .	2.0	20
13	Depletion of Arg/Abl2 improves endothelial cell adhesion and prevents vascular leak during inflammation. Angiogenesis, 2021, 24, 677-693.	7.2	19
14	In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time. Journal of Visualized Experiments, 2020, , .	0.3	10
15	Elevated acute phase proteins affect pharmacokinetics in COVIDâ€19 trials: Lessons from the CounterCOVID ―imatinib study. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1497-1511.	2.5	8
16	Why vessels do matter in pulmonary disease. Thorax, 2016, 71, 767-769.	5.6	6
17	The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19. Trials, 2022, 23, 158.	1.6	6
18	Bosutinib reduces endothelial permeability and organ failure in a rat polytrauma transfusion model. British Journal of Anaesthesia, 2021, 126, 958-966.	3.4	4

#	Article	IF	CITATIONS
19	Vanishing vessels aboding pulmonary disease: a role for VEGFR2. European Respiratory Journal, 2020, 55, 2000326.	6.7	3
20	Multilevel omics: A next step on the way to understanding pulmonary arterial hypertension?. Thorax, 2019, 74, 317-318.	5.6	1
21	Application of [18F]FLTâ€PET in pulmonary arterial hypertension: a clinical study in pulmonary arterial hypertension patients and unaffected bone morphogenetic protein receptor type 2Åmutation carriers. Pulmonary Circulation, 2021, 11, 1-9.	1.7	1